Related Experiment Video
Updated: May 6, 2026
10:36
A Swine Model of Neonatal Asphyxia
Published on: October 11, 2011
14.3K
Keeping the Ductus Arteriosus Patent: Current Strategy and Perspectives
Anastasios Chatziantoniou1, Filippos-Paschalis Rorris2, George Samanidis3
1Department of Cardiology, Onassis Hospital, 17674 Athens, Greece.
Diagnostics (Basel, Switzerland)
|February 13, 2025
Summary
Patent ductus arteriosus (PDA) is a critical lifeline in some congenital heart disease patients. This review explores mechanisms to keep the PDA open, focusing on pharmacological and surgical interventions.
Area of Science:
- Cardiovascular Medicine
- Pediatric Cardiology
- Neonatology
Background:
- Patent ductus arteriosus (PDA) is a common condition in infants and adults.
- While often pathological, PDA is essential for survival in ductal-dependent congenital heart disease.
- Understanding PDA's role is crucial for managing specific pediatric cardiovascular conditions.
Purpose of the Study:
- To review the anatomical and biochemical mechanisms influencing PDA.
- To focus on ductal-dependent congenital heart disease and methods for maintaining PDA patency.
- To explore pharmacological, surgical, and interventional strategies for circulation support.
Main Methods:
- Literature review of anatomical and biochemical factors affecting PDA.
- Analysis of pharmacological and biochemical approaches for maintaining ductus arteriosus patency.
- Evaluation of surgical and interventional options for circulation maintenance in PDA-dependent patients.
Main Results:
- PDA plays a dual role: a problem in general cases but a lifeline in congenital heart disease.
- Current knowledge highlights the need for better understanding of ductus arteriosus endothelium.
- Various pharmacological and surgical interventions exist for managing PDA.
Conclusions:
- PDA management requires tailored approaches based on its role in congenital heart disease.
- Further research into the ductus arteriosus endothelium could reveal new therapeutic targets.
- Optimizing pharmacological maintenance of PDA patency is a key area for future development.
Related Concept Videos
01:14Fetal Circulation
5.1K
Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
5.1K
01:25Mitral Regurgitation III: Medical Management
691
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
691
01:26Mitral Stenosis III: Medical Management
539
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
539
01:25Aortic Regurgitation III: Medical Management
599
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
599
01:17Aortic Regurgitation IV: Nursing Management
458
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
458
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
462
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
462